Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analysesEun Young Kang, P. Mackenzie, Dane Cheasley et al.|Modern Pathology|2020Cited by 43
Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp> CD8 <sup>+</sup> TIL </scp> infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomasKarolin Heinze, Yurii B. Shvetsov, Nicola S. Meagher et al.|The Journal of Pathology|2021Cited by 42
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Alexander Hein, Joshua Millstein et al.|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2021Cited by 23
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian CarcinomaKarolin Heinze, Yurii B. Shvetsov, Tayyebeh M. Nazeran et al.|medRxiv|2021Cited by 4